GlassScriptPhysician profile
Robert P Kauffman
NPI 1841222049
$46,474.25
in general payments reported to CMS, 2019-2025
12 companies · $4,558 in 2025
The $4,558 reported for 2025 was more than what 95% of Reproductive Endocrinology providers received nationally (typical 2025 total: $140).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,293 · 2020: $37.15 · 2021: $7,128 · 2022: $4,281 · 2023: $21K · 2024: $6,359 · 2025: $4,558.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $17K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $13K · Travel and Lodging: $1,441 · Food and Beverage: $702.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16,717.50 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $12,873.77 |
| Travel and Lodging | $1,441.26 |
| Food and Beverage | $702.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $23,352.45 | 2021-2025 | Nexplanon |
| Astellas Pharma US INC | $18,002.30 | 2022-2025 | Veozah |
| Merck Sharp & Dohme LLC | $4,620.51 | 2019-2021 | |
| Coopersurgical, INC. | $184.41 | 2023 | Advincula Delineator Uterine Manipulator, Summit Doppler |
| Mayne Pharma Commercial LLC | $79.44 | 2023 | |
| Abbvie INC. | $72.17 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $48.92 | 2019-2021 | |
| Baudax Bio INC. | $41.27 | 2022 | |
| Heron Therapeutics, INC. | $41.04 | 2024 | Zynrelef |
| Viiv Healthcare Company | $17.10 | 2022 | |
| Medtronic, INC. | $14.64 | 2025 | Ligasure |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Kauffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.